Can AI-assisted microscope facilitate breast HER2 interpretation? A multi-institutional ring study

被引:0
|
作者
Meng Yue
Jun Zhang
Xinran Wang
Kezhou Yan
Lijing Cai
Kuan Tian
Shuyao Niu
Xiao Han
Yongqiang Yu
Junzhou Huang
Dandan Han
Jianhua Yao
Yueping Liu
机构
[1] The Fourth Hospital of Hebei Medical University,Department of Pathology
[2] Nanshan District,Tencent AI Lab
来源
Virchows Archiv | 2021年 / 479卷
关键词
Artificial intelligence–assisted microscope; Breast cancer; HER2;
D O I
暂无
中图分类号
学科分类号
摘要
The level of human epidermal growth factor receptor-2 (HER2) protein and gene expression in breast cancer is an essential factor in judging the prognosis of breast cancer patients. Several investigations have shown high intraobserver and interobserver variability in the evaluation of HER2 staining by visual examination. In this study, we aim to propose an artificial intelligence (AI)–assisted microscope to improve the HER2 assessment accuracy and reliability. Our AI-assisted microscope was equipped with a conventional microscope with a cell-level classification-based HER2 scoring algorithm and an augmented reality module to enable pathologists to obtain AI results in real time. We organized a three-round ring study of 50 infiltrating duct carcinoma not otherwise specified (NOS) cases without neoadjuvant treatment, and recruited 33 pathologists from 6 hospitals. In the first ring study (RS1), the pathologists read 50 HER2 whole-slide images (WSIs) through an online system. After a 2-week washout period, they read the HER2 slides using a conventional microscope in RS2. After another 2-week washout period, the pathologists used our AI microscope for assisted interpretation in RS3. The consistency and accuracy of HER2 assessment by the AI-assisted microscope were significantly improved (p < 0.001) over those obtained using a conventional microscope and online WSI. Specifically, our AI-assisted microscope improved the precision of immunohistochemistry (IHC) 3 + and 2 + scoring while ensuring the recall of fluorescent in situ hybridization (FISH)–positive results in IHC 2 + . Also, the average acceptance rate of AI for all pathologists was 0.90, demonstrating that the pathologists agreed with most AI scoring results.
引用
收藏
页码:443 / 449
页数:6
相关论文
共 35 条
  • [1] Can AI-assisted microscope facilitate breast HER2 interpretation? A multi-institutional ring study
    Yue, Meng
    Zhang, Jun
    Wang, Xinran
    Yan, Kezhou
    Cai, Lijing
    Tian, Kuan
    Niu, Shuyao
    Han, Xiao
    Yu, Yongqiang
    Huang, Junzhou
    Han, Dandan
    Yao, Jianhua
    Liu, Yueping
    VIRCHOWS ARCHIV, 2021, 479 (03) : 443 - 449
  • [2] Utilization of HER2 Genetic Testing in a Multi-Institutional Observational Study
    Goddard, Katrina A. B.
    Bowles, Erin J. Aiello
    Feigelson, Heather Spencer
    Habel, Laurel A.
    Alford, Sharon Hensley
    McCarty, Catherine A.
    Nekhlyudov, Larissa
    Onitilo, Adedayo A.
    Rahm, Alanna K.
    Webster, Jennifer A.
    AMERICAN JOURNAL OF MANAGED CARE, 2012, 18 (11) : 704 - 712
  • [3] Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry
    Robbins, Charles J.
    Fernandez, Aileen I.
    Han, Gang
    Wong, Serena
    Harigopal, Malini
    Podoll, Mirna
    Singh, Kamaljeet
    Ly, Amy
    Kuba, M. Gabriela
    Wen, Hannah
    Sanders, Mary Ann
    Brock, Jane
    Wei, Shi
    Fadare, Oluwole
    Hanley, Krisztina
    Jorns, Julie
    Snir, Olivia L.
    Yoon, Esther
    Rabe, Kim
    Soong, T. Rinda
    Reisenbichler, Emily S.
    Rimm, David L.
    MODERN PATHOLOGY, 2023, 36 (01)
  • [4] Evaluation of the HER2 and Hormone Receptor Status in Metastatic Breast Cancer Using Cell Blocks: A Multi-Institutional Study
    Nishimura, Rieko
    Murata, Yuya
    Mori, Kiyoshi
    Yamashiro, Katsushige
    Kuraoka, Kazuya
    Ichihara, Shu
    Taguchi, Kenichi
    Suzuki, Hiroyoshi
    Ito, Masahiro
    Yamashita, Natsumi
    ACTA CYTOLOGICA, 2018, 62 (04) : 288 - 294
  • [5] Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study
    Buza, Natalia
    Euscher, Elizabeth D.
    Matias-Guiu, Xavier
    McHenry, Austin
    Oliva, Esther
    Ordulu, Zehra
    Parra-Herran, Carlos
    Rottmann, Douglas
    Turner, Bradley M.
    Wong, Serena
    Hui, Pei
    MODERN PATHOLOGY, 2021, 34 (06) : 1194 - 1202
  • [6] Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study
    Erickson, Britt K.
    Najjar, Omar
    Damast, Shari
    Blakaj, Adriana
    Tymon-Rosario, Joan
    Shahi, Maryam
    Santin, Alessandro
    Klein, Molly
    Dolan, Michelle
    Cimino-Mathews, Ashley
    Buza, Natalia
    Ferriss, J. Stuart
    Stone, Rebecca L.
    Khalifa, Mahmoud
    Fader, Amanda N.
    GYNECOLOGIC ONCOLOGY, 2020, 159 (01) : 17 - 22
  • [7] A Prospective Multi-Institutional Observational Study on ER, PR, HER2/NEU, and Ki-67 Expression and Discordance Pattern in Primary and Metastatic and Recurrent Carcinoma Breast and Its Therapeutic Implications and Prognostic Outcome
    Satishkumar, Maheswaran
    Ramesh, Muthuvel
    Sanjive, Jeevan G.
    INDIAN JOURNAL OF SURGICAL ONCOLOGY, 2023, 14 (01) : 72 - 80
  • [8] What Causes Discrepancies in HER2 Testing for Breast Cancer? A Japanese Ring Study in Conjunction With the Global Standard
    Umemura, Shinobu
    Osamura, R. Yoshiyuki
    Akiyama, Futoshi
    Honma, Keiichi
    Kurosumi, Masafumi
    Sasano, Hironobu
    Toyoshima, Satoshi
    Tsuda, Hitoshi
    Rueschoff, Josef
    Sakamoto, Goi
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2008, 130 (06) : 883 - 891
  • [9] Improving Ki67 assessment concordance by the use of an artificial intelligence-empowered microscope: a multi-institutional ring study
    Cai, Lijing
    Yan, Kezhou
    Bu, Hong
    Yue, Meng
    Dong, Pei
    Wang, Xinran
    Li, Lina
    Tian, Kuan
    Shen, Haocheng
    Zhang, Jun
    Shang, Jiuyan
    Niu, Shuyao
    Han, Dandan
    Ren, Chen
    Huang, Junzhou
    Han, Xiao
    Yao, Jianhua
    Liu, Yueping
    HISTOPATHOLOGY, 2021, 79 (04) : 544 - 555
  • [10] Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
    Jennifer R. Bellon
    Hao Guo
    William T. Barry
    Chau T. Dang
    Denise A. Yardley
    Beverly Moy
    P. Kelly Marcom
    Kathy S. Albain
    Hope S. Rugo
    Matthew Ellis
    Antonio C. Wolff
    Lisa A. Carey
    Beth A. Overmoyer
    Ann H. Partridge
    Clifford A. Hudis
    Ian Krop
    Harold J. Burstein
    Eric P. Winer
    Sara M. Tolaney
    Breast Cancer Research and Treatment, 2019, 176 : 303 - 310